我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Precision Medicine in Oncology: Sentinel Lymph Node Biopsy as a Diagnostic and Therapeutic Tool

Jelley Naylor

The era of precision medicine has ushered in a paradigm shift in oncology, emphasizing tailored approaches to diagnosis and treatment. Sentinel lymph node biopsy (SLNB) has emerged as a pivotal diagnostic and therapeutic tool, exemplifying the principles of precision medicine. This review explores the multifaceted role of SLNB in the context of oncology, highlighting its significance as a precise, minimally invasive technique with far-reaching implications. SLNB, originally developed for melanoma and breast cancer, has redefined the landscape of nodal staging in surgical oncology. By identifying the sentinel lymph node the initial node in the lymphatic drainage pathway from a primary tumor SLNB offers unparalleled precision in assessing nodal involvement. Its diagnostic accuracy and prognostic value have been well-established, allowing for early detection of metastatic disease and informed therapeutic decisions. In breast cancer, SLNB has facilitated personalized surgical approaches, enabling the avoidance of unnecessary axillary lymph node dissections and their associated morbidity. Its role extends beyond diagnosis, impacting adjuvant treatment recommendations and long-term outcomes.